AGR:LSE-Assura Plc (GBX)

COMMON STOCK | REIT—Healthcare Facilities | LSE

Last Closing Price

GBX 73.60

Change

-0.50 (-0.67)%

Market Cap

GBX 1.97B

Volume

2.58M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 31 March 2020, Assura's property portfolio was valued at £2,139 million.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for REIT—Healthcare Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PHP:LSE Primary Health Properties PLC

-0.60 (-0.42%)

GBX1.87B 19.59 N/A
THRL:LSE Target Healthcare REIT plc

+0.40 (+0.36%)

GBX0.52B 15.65 26.25
IHR:LSE Impact Healthcare REIT plc

N/A

GBX0.34B 11.96 N/A

ETFs Containing AGR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (REIT—Healthcare Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.40% 50% F 42% F
Dividend Return 1.83% 50% F 53% F
Total Return -3.57% 50% F 43% F
Trailing 12 Months  
Capital Gain -3.29% 50% F 41% F
Dividend Return 2.78% 50% F 70% C-
Total Return -0.50% 50% F 45% F
Trailing 5 Years  
Capital Gain 33.17% 100% A+ 59% F
Dividend Return 21.82% 100% A+ 77% C+
Total Return 54.99% 100% A+ 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 9.66% N/A N/A 66% D
Dividend Return 4.25% N/A N/A 81% B-
Total Return 13.91% N/A N/A 73% C
Risk Return Profile  
Volatility (Standard Deviation) 15.29% N/A N/A 62% D-
Risk Adjusted Return 91.02% N/A N/A 88% B+
Market Capitalization 1.97B 100% A+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(REIT—Healthcare Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.03 25% F 38% F
Price/Book Ratio 1.56 25% F 43% F
Price / Cash Flow Ratio 29.79 25% F 13% F
EV/EBITDA 27.55 50% F 18% F
Management Effectiveness  
Return on Equity 6.20% 50% F 65% D
Return on Invested Capital 4.56% 50% F 53% F
Return on Assets 2.51% 25% F 61% D-
Debt to Equity Ratio 63.77% 100% A+ 29% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.10 75% C 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.